VirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 Data
🤖 D.R.A.F.T. Summary
VirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to
LONDON — VirTus Respiratory Research Ltd, a specialist respiratory contract research organisation (CRO), founded by Imperial College London investigators Professor Sebastian Johnston and Dr Michael Edwards, today highlighted its role in the preclinical development of Apollo Therapeutics’ and Imperial’s APL-10456, following the announcement of positive initial data from the vaccine’s Phase 1 clinical trial. VirTus […]
Outlets covering this story
Financial Post
CENTER
Only one perspective covered this story — no diversity detected
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →